NIKKEI 225
38,757.55 +267.38 (+0.69%) HANG SENG
18,446.59 +21.63 (+0.12%) CRUDE OIL
74.47 +0.40 (+0.54%) GOLD FUTURES
2,386.80 +11.30 (+0.48%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,419.29 -3.93 (-0.01%)
NVO Jan 2026 190.000 put
| Previous close | 56.17 |
| Open | N/A |
| Bid | 63.45 |
| Ask | 66.35 |
| Strike | 190.00 |
| Expiry date | 2026-01-16 |
| Day's range | 56.17 - 56.17 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ReutersNovo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world's highest number of people who are overweight or obese. Ozempic won approval from China in 2021 and Novo Nordisk saw sales of the drug in the greater China region double to 4.8 billion Danish Krone ($698 million) last year.
Investor's Business DailyNetflix, Novo Nordisk And These IPOs Fuel Smorgasbord Of Breakouts
Netflix and Novo Nordisk are just two names on this smorgasbord of stocks setting up or soaring past new buy points.
Investor's Business DailyObesity Drug Leader In Buy Zone After Huge Gains
Novo Nordisk is in a buy zone after a 39% gain year to date. The anti-obesity drug market is expect to grow to $4.4 billion by 2032.
